Unprecedented ‘Meta’ Domain Name Registrations
Client Alert | 1 min read | 11.02.21
Thursday’s announcement that Facebook is rebranding itself as ‘Meta’ resulted in an unprecedented number of new domain name registrations. Since Friday, we have identified over 48,000 new ‘meta’ domain names by way of the award-winning and bespoke brand protection and cybersecurity platform designed and engineered by Crowell & Moring senior counsel Alexander Urbelis.
Critically, a significant number of these newly-registered domains incorporate the names of companies and organizations, or well-known trademarks, e.g., meta-[company name].com or meta[trademark].com. Potentially used for phishing or misinformation, these domains may present cybersecurity issues, and may also constitute threats to brand strength. As a result, we recommend that companies preemptively register domains with the above syntax to prevent them from falling into the hands of cybersquatters or threat actors.
This unprecedented onslaught of domain name registrations also highlights the crossover and complementary nature of brand protection and cybersecurity efforts, giving companies the opportunity to strengthen their cybersecurity posture by protecting valuable trademark rights and prioritizing unauthorized domain registrations en masse.
Contacts
Insights
Client Alert | 4 min read | 04.10.25
Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels”
In Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., C.A. No. 20-1630 (D. Del.), brand manufacturer Amarin brought an induced infringement claim against Hikma’s generic icosapent ethyl product, which lists Amarin’s Vascepa® as the reference listed drug. Vascepa was originally approved by the U.S. Food and Drug Administration (“FDA”) to treat severe hypertriglyceridemia, and later, Amarin obtained patents and approval for Vascepa as a treatment to reduce cardiovascular risk in certain patient populations. Hikma’s Abbreviated New Drug Application (“ANDA”) for generic icosapent ethyl included a Section viii statement that Hikma was not seeking approval for the patented cardiovascular indication along with a “skinny label” that included only the indication for severe hypertriglyceridemia.
Client Alert | 1 min read | 04.09.25
Client Alert | 12 min read | 04.09.25
Client Alert | 4 min read | 04.07.25
